CClinicalTrials.gg
Not yet recruitingNCT07782892OXYURG-IPAUpdated Aug 24, 2026

Impact of an Emergency Advanced Practice Nurse on Complications After Home Discharge of Oxygen-Dependent Patients Managed in the Emergency Department: A Quantitative and Qualitative Study

An interventional study of APN-physician team management of the Oxy-Urg pathway and Usual care: physician-alone management of the Oxy-Urg pathway in Acute Respiratory Conditions Requiring Oxygen Therapy, Advanced Practice Nursing and Home Care Services, sponsored by University Hospital, Strasbourg, France. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by University Hospital, Strasbourg, France · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Since the COVID-19 pandemic, discharging patients home on low-flow oxygen therapy has proven to be a safe and effective alternative to hospitalization, helping to relieve overcrowded hospitals while ensuring continuity of care. At the investigating emergency department, a dedicated care pathway ("Oxy-Urg") already allows selected oxygen-dependent patients to return home with a home-care provider, regardless of the cause of their breathlessness, once their condition is stable.

This study evaluates whether managing these patients with a team combining an emergency advanced practice nurse (APN) and an emergency physician, rather than a physician alone, improves the organization of care and reduces complications after home discharge.

Adult oxygen-dependent patients eligible for the Oxy-Urg pathway are randomly assigned (1:1) to management by an APN-physician team (intervention group) or by a physician alone (control group). Both groups then receive the usual Oxy-Urg pathway (home oxygen therapy, provider tele-monitoring, community nurse and general practitioner follow-up).

The main goal is to compare the number of organizational adverse events occurring between inclusion and Day 28 between the two groups. The study also assesses clinical deterioration after discharge, the time professionals spend setting up the pathway, and, through interviews and a focus group, the experience of patients and professionals. The hypothesis is that the APN-physician team allows a more efficient organization and improves the patient experience, supporting the sustainability and wider use of this pathway.

02

Conditions studied

  • Acute Respiratory Conditions Requiring Oxygen Therapy
  • Advanced Practice Nursing
  • Home Care Services
  • Home Oxygen Therapy
  • Emergency Service, Hospital
  • Patient Discharge

Browse trials for

Keywords

  • Advanced practice nurse
  • Emergency department
  • Home oxygen therapy
  • Early supported discharge
  • Care pathway
  • Organizational adverse events
  • Patient experience
  • Care organization
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adult patient (>= 18 years)
  • Affiliated to a social health insurance scheme
  • Able to understand the objectives and risks of the research and to give dated, signed informed consent
  • Oxygen-dependent patient eligible for the Oxy-Urg pathway, meeting all of the following:

    • Stable for more than 12 hours on oxygen therapy in the emergency department
    • Oxygen requirement \<= 2 L/min (no upward change for 12 hours)
    • Not socially isolated (relatives able to readily help the patient, living geographically close)
    • Residing within the provider's geographical area (Bas-Rhin department)
    • No known pregnancy at inclusion

Exclusion criteria

Exclusion Criteria:

  • Clinical condition requiring hospitalization (decided by the senior physician, per standard of care)
  • Patient's refusal to enter the pathway
  • Patient managed outside the emergency APN's working hours
  • End-of-life patient
  • Unable to give informed consent (including insufficient understanding of French)
  • Subject in an exclusion period
  • Subject under legal protection
  • Subject under guardianship or curatorship
04

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
170 participants (estimated)

Study arms

  • Experimental
    Advanced practice nurse-physician team

    Other: APN-physician team management of the Oxy-Urg pathway

  • Active comparator
    Emergency physician alone (usual care)

    Other: Usual care: physician-alone management of the Oxy-Urg pathway

Interventions

  • OtherAPN-physician team management of the Oxy-Urg pathway

    Organizational intervention: the emergency advanced practice nurse and the emergency physician jointly manage the inclusion of the patient in the Oxy-Urg pathway and the organization of the home discharge on oxygen.

  • OtherUsual care: physician-alone management of the Oxy-Urg pathway

    Usual care

05

What researchers measure

Primary outcomes

  1. Proportion of patients with at least one organizational adverse event related to home discharge on oxygen

    At least one of the following organizational adverse events: (1) total pathway inclusion time greater than 20 minutes; (2) administrative error or omission regarding prescriptions, the liaison file or handover; (3) time to home oxygen availability exceeding the protocol target; (4) initial technical difficulty of the equipment requiring corrective action by the provider; (5) non-compliance with instructions given to home caregivers, evidenced by a documented non-conformity; (6) nurse visit not compliant with the prescription, observed and recorded.

    Time frame: From inclusion (Day 0) to Day 28

06

Study locations

1 site
07

Registry details

Key details

Study ID
NCT07782892
Lead sponsor
University Hospital, Strasbourg, France
Responsible party
Sponsor
First posted
Aug 24, 2026
Start date
Oct 30, 2026 (estimated)
Primary completion
Oct 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Aug 24, 2026

Study contacts

Aline CHENOU
Contact
aline.chenou@chru-strasbourg.fr
0033369551460

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion